论文部分内容阅读
目的 研究多药耐药相关蛋白 (MRP)在人恶性黑色素瘤转移性淋巴结组织中的表达及其与以顺铂、氮唏咪胺为主的联合化疗 (PDBV)疗效的关系。方法 免疫组织化学技术对石蜡包埋组织标本进行检测。结果 2 6例晚期恶性黑色素瘤患者转移性淋巴结组织中MRP表达阳性检出率为 38 5 % ( 10 / 2 6 )。MRP表达与PDBV化疗疗效无显著相关 (P >0 0 5 )。结论 MRP在人恶性黑色素瘤转移性淋巴结组织中有一定程度表达 ,但人恶性黑色素瘤的多药耐药可能有其它重要因素参与
Objective To investigate the expression of multidrug resistance-associated protein (MRP) in human malignant melanoma metastatic lymph nodes and its relationship with the efficacy of cisplatin and azimidomide combined with chemotherapy (PDBV). Methods Immunohistochemistry was used to detect paraffin-embedded tissue specimens. Results The positive rate of MRP expression in metastatic lymph nodes in 26 patients with advanced malignant melanoma was 38 5% (10/2 6). There was no significant correlation between MRP expression and PDBV chemotherapy (P> 0.05). Conclusion MRP is expressed in metastatic lymph node tissue of human malignant melanoma to some extent. However, there are other important factors involved in the multidrug resistance of human malignant melanoma